Merus Stock

Merus EBIT

Delisted·Dec 29, 2025

The EBIT of Merus (MRUS) as of Aug 6, 2026 is -262.63 M USD. In the previous year, EBIT was -141.80 M USD — a change of 85.21% (lower).

EBIT

-262.63 MUSD

YoY

85.21%

Last updated:

In 2026, Merus's EBIT was -262.63 M USD, a 85.21% increase from the -141.80 M USD EBIT recorded in the previous year.

The Merus EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
YEAREBIT (undefined USD)
2029 est -
2028 est -
2027 est -
2026 est -
2025 est -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
Access this data via the Eulerpool API

Merus Revenue

Merus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
38.84 M USD
-149.46 M USD
-122.52 M USD
Jan 1, 2023
39.81 M USD
-141.80 M USD
-140.34 M USD
Jan 1, 2024
34.88 M USD
-262.63 M USD
-207.85 M USD
Jan 1, 2025 (e)
55.28 M USD
-53.56 M USD
-438.11 M USD
Jan 1, 2026 (e)
42.47 M USD
-49.33 M USD
-389.54 M USD
Jan 1, 2027 (e)
188.58 M USD
-188.58 M USD
-283.44 M USD
Jan 1, 2028 (e)
588.92 M USD
-588.92 M USD
13.22 M USD
Jan 1, 2029 (e)
1.22 B USD
-1.22 B USD
406.68 M USD

Merus Margins

Merus stock margins

The Merus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
74.37 %
-384.84 %
-315.48 %
Jan 1, 2023
73.62 %
-356.22 %
-352.56 %
Jan 1, 2024
37.15 %
-752.96 %
-595.93 %
Jan 1, 2025 (e)
37.15 %
-96.88 %
-792.52 %
Jan 1, 2026 (e)
37.15 %
-116.14 %
-917.23 %
Jan 1, 2027 (e)
37.15 %
-100.00 %
-150.30 %
Jan 1, 2028 (e)
37.15 %
-100.00 %
2.24 %
Jan 1, 2029 (e)
37.15 %
-100.00 %
33.21 %

Merus Stock analysis

What does Merus do? Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Merus's EBIT

Merus's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Merus's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Merus's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Merus’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Merus stock

EBIT of Merus is -262.63 M USD in 2026.

EBIT of Merus changed from -141.80 M USD to -262.63 M USD, representing a 85.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Merus since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Merus historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Merus

All Key Metrics — Merus